Literature DB >> 15155925

Infectious diseases. One year after outbreak, SARS virus yields some secrets.

Martin Enserink.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155925     DOI: 10.1126/science.304.5674.1097

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  12 in total

1.  Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.

Authors:  Yuxian He; Jingjing Li; Susanne Heck; Sara Lustigman; Shibo Jiang
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display.

Authors:  Xiaoping Kang; Bao-An Yang; Yuyang Hu; Hui Zhao; Wei Xiong; Yinhui Yang; Bingyin Si; Qingyu Zhu
Journal:  Clin Vaccine Immunol       Date:  2006-08

Review 3.  SARS molecular epidemiology: a Chinese fairy tale of controlling an emerging zoonotic disease in the genomics era.

Authors:  Guo-ping Zhao
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-06-29       Impact factor: 6.237

4.  Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.

Authors:  Zhiwei Chen; Linqi Zhang; Chuan Qin; Lei Ba; Christopher E Yi; Fengwen Zhang; Qiang Wei; Tian He; Wenjie Yu; Jian Yu; Hong Gao; Xinming Tu; Agegnehu Gettie; Michael Farzan; Kwok-Yung Yuen; David D Ho
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry.

Authors:  Yuxian He; Yusen Zhou; Pamela Siddiqui; Shibo Jiang
Journal:  Biochem Biophys Res Commun       Date:  2004-12-10       Impact factor: 3.575

6.  Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates.

Authors:  Shih-Jen Liu; Chih-Hsiang Leng; Shu-Pei Lien; Hsiang-Yun Chi; Chiung-Yi Huang; Chang-Ling Lin; Wei-Cheng Lian; Chi-Ju Chen; Shie-Liang Hsieh; Pele Chong
Journal:  Vaccine       Date:  2006-02-08       Impact factor: 3.641

Review 7.  Cellular entry of the SARS coronavirus.

Authors:  Heike Hofmann; Stefan Pöhlmann
Journal:  Trends Microbiol       Date:  2004-10       Impact factor: 17.079

Review 8.  Severe acute respiratory syndrome.

Authors:  J S M Peiris; Y Guan; K Y Yuen
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

Review 9.  Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention.

Authors:  Kap-Sun Yeung; Gregory A Yamanaka; Nicholas A Meanwell
Journal:  Med Res Rev       Date:  2006-07       Impact factor: 12.944

10.  Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.

Authors:  Yuxian He; Qingyu Zhu; Shuwen Liu; Yusen Zhou; Baoan Yang; Jiaming Li; Shibo Jiang
Journal:  Virology       Date:  2005-03-30       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.